{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:24:47Z","timestamp":1791674687277,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jval.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T04:17:57Z","timestamp":1648181877000},"page":"1344-1351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Alice J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius N.","family":"Lakdawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jval.2022.02.007_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.jval.2022.02.007_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jval.2022.02.007_bib3","first-page":"379","article-title":"The potential impact of CAR T-cell\u00a0treatment delays on society","volume":"25","author":"Thornton Snider","year":"2019","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2022.02.007_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00086","article-title":"Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model","volume":"3","author":"Tully","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"10.1016\/j.jval.2022.02.007_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2022.02.007_bib7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1159\/000487288","article-title":"Ratio of immune response to tumor burden predicts survival via regulating functions of lymphocytes and monocytes in diffuse large B-cell lymphoma","volume":"45","author":"Ji","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"34","key":"10.1016\/j.jval.2022.02.007_bib8","doi-asserted-by":"crossref","first-page":"23620","DOI":"10.18632\/oncotarget.25306","article-title":"A\u00a0high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival","volume":"9","author":"Keane","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jval.2022.02.007_bib9","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.21873\/anticanres.11613","article-title":"Prediction of prognosis for patients with diffuse large B-cell lymphoma refractory to or in first relapse after initial R-CHOP therapy: a single-institution study","volume":"37","author":"Yamamoto","year":"2017","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.jval.2022.02.007_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000353127","article-title":"Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma","volume":"130","author":"Hong","year":"2013","journal-title":"Acta Haematol"},{"issue":"10","key":"10.1016\/j.jval.2022.02.007_bib11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-014-2115-z","article-title":"The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab","volume":"93","author":"Park","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jval.2022.02.007_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8","article-title":"Prognostic significance of serum lactate dehydrogenase in malignant lymphoma","volume":"46","author":"Schneider","year":"1980","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jval.2022.02.007_bib13","first-page":"637","article-title":"Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore\u2019s private insurance payer\u2019s perspective","volume":"24","author":"Wang","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.jval.2022.02.007_bib14","doi-asserted-by":"crossref","first-page":"506.e1","DOI":"10.1016\/j.jtct.2021.03.005","article-title":"Cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma in Japan","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jval.2022.02.007_bib15","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s12325-021-01767-x","article-title":"Cost-effectiveness of tisagenlecleucel in paediatric acute lymphoblastic leukaemia (pALL) and adult diffuse large B-cell lymphoma (DLBCL) in Switzerland","volume":"38","author":"Moradi-Lakeh","year":"2021","journal-title":"Adv Ther"},{"issue":"PCN177","key":"10.1016\/j.jval.2022.02.007_bib16","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jval.2018.09.260","article-title":"Cost-effectiveness of tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma: a Canadian societal perspective","volume":"21","author":"Yang","year":"2018","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2022.02.007_bib17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.clinthera.2021.06.011","article-title":"Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States","volume":"43","author":"Qi","year":"2021","journal-title":"Clin Ther"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.02.007_bib18","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the JULIET trial","volume":"134","author":"Westin","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jval.2022.02.007_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1257\/0002828053828563","article-title":"The quantity and quality of life and the evolution of world inequality","volume":"95","author":"Becker","year":"2005","journal-title":"Am Econ Rev"},{"issue":"10","key":"10.1016\/j.jval.2022.02.007_bib20","doi-asserted-by":"crossref","first-page":"14083","DOI":"10.1007\/s13277-016-5228-2","article-title":"Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU\/L","volume":"37","author":"Liu","year":"2016","journal-title":"Tumour Biol"},{"issue":"3","key":"10.1016\/j.jval.2022.02.007_bib21","first-page":"189","article-title":"The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma","volume":"35","author":"William","year":"2013","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"1","key":"10.1016\/j.jval.2022.02.007_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12885-016-3013-7","article-title":"Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study","volume":"17","author":"Song","year":"2017","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.jval.2022.02.007_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s11538-015-0110-8","article-title":"Estimating tumor growth rates in\u00a0vivo","volume":"77","author":"Talkington","year":"2015","journal-title":"Bull Math Biol"},{"issue":"8","key":"10.1016\/j.jval.2022.02.007_bib24","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/0008-5472.CAN-06-3822","article-title":"Specific growth rate versus doubling time for quantitative characterization of tumor growth rate","volume":"67","author":"Mehrara","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jval.2022.02.007_bib25","author":"Killmurray"},{"key":"10.1016\/j.jval.2022.02.007_bib28","author":"Andrews"},{"key":"10.1016\/j.jval.2022.02.007_bib30","author":"Solbach"},{"key":"10.1016\/j.jval.2022.02.007_bib31","unstructured":"Bethge W, Holtick U, Wagner-Drouet E, et al. Standard-of-care CAR-T cell therapy for large B-cell lymphoma: real world data Germany. Paper presented at: European Society for Blood and Marrow Transplantation Annual Meeting; Virtual Conference; 2021."},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.02.007_bib32","article-title":"A\u00a0multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jval.2022.02.007_bib33","first-page":"159","article-title":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","volume":"68","author":"Yassine","year":"2020","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jval.2022.02.007_bib34","unstructured":"Le Gouill S. Clinical trial efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma is mirrored in the real world. Paper presented at: European Hematology Association Congress; Virtual Conference; 2021."},{"issue":"10","key":"10.1016\/j.jval.2022.02.007_bib35","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jval.2022.02.007_bib36","first-page":"81","article-title":"Outcome of high-grade lymphoma patients treated with CD19 CAR-T\u2014updated real-world experience in the UK","volume":"4","author":"Kuhnl","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.jval.2022.02.007_bib37","author":"Baker"},{"key":"10.1016\/j.jval.2022.02.007_bib38","author":"Sabzevari"},{"key":"10.1016\/j.jval.2022.02.007_bib39","author":"Vigant"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T22:13:05Z","timestamp":1728943985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1098301522001097"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.02.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}